Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Nestle price target raised to CHF 145 from CHF 135 at JPMorgan » 13:00
11/30/21
11/30
13:00
11/30/21
13:00
NSRGY

Nestle

$130.32 /

-0.0899 (-0.07%)

JPMorgan analyst Celine…

JPMorgan analyst Celine Pannuti raised the firm's price target on Nestle to CHF 145 from CHF 135 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
NSRGY Nestle
$130.32 /

-0.0899 (-0.07%)

NSRGY Nestle
$130.32 /

-0.0899 (-0.07%)

11/18/21 Morgan Stanley
Nestle price target raised to CHF 135 from CHF 127 at Morgan Stanley
10/22/21 Barclays
Nestle price target raised to CHF 130 from CHF 125 at Barclays
10/21/21 UBS
Nestle price target raised to CHF 135 from CHF 130 at UBS
08/26/21 Societe Generale
Nestle price target raised to CHF 134 from CHF 124 at Societe Generale
NSRGY Nestle
$130.32 /

-0.0899 (-0.07%)

NSRGY Nestle
$130.32 /

-0.0899 (-0.07%)

Over a week ago
Recommendations
Nestle price target raised to CHF 135 from CHF 127 at Morgan Stanley » 14:07
11/18/21
11/18
14:07
11/18/21
14:07
NSRGY

Nestle

$133.07 /

+0.35 (+0.26%)

Morgan Stanley analyst…

Morgan Stanley analyst Pinar Ergun raised the firm's price target on Nestle to CHF 135 from CHF 127 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
NSRGY Nestle
$133.07 /

+0.35 (+0.26%)

NSRGY Nestle
$133.07 /

+0.35 (+0.26%)

10/22/21 Barclays
Nestle price target raised to CHF 130 from CHF 125 at Barclays
10/21/21 UBS
Nestle price target raised to CHF 135 from CHF 130 at UBS
08/26/21 Societe Generale
Nestle price target raised to CHF 134 from CHF 124 at Societe Generale
07/02/21 Deutsche Bank
Nestle price target raised to CHF 118 from CHF 115 at Deutsche Bank
NSRGY Nestle
$133.07 /

+0.35 (+0.26%)

NSRGY Nestle
$133.07 /

+0.35 (+0.26%)

Over a month ago
Hot Stocks
Dada Nexus, Nestle expand marketing and digitalization cooperation » 05:13
10/28/21
10/28
05:13
10/28/21
05:13
DADA

Dada Nexus

$21.95 /

+0.32 (+1.48%)

, NSRGY

Nestle

$128.20 /

+0.67 (+0.53%)

Dada Group (DADA) and…

Dada Group (DADA) and Nestle (NSRGY) announced that they would strengthen cooperation on omni-channel marketing and digitalization. Philip Kuai, founder, chairman and CEO of Dada Group, and Rashid Qureshi, chairman and CEO of Nestle Greater China Region, signed a joint business plan in Beijing. In the cooperation, Dada Group and Nestle collaborate in uni-marketing, omni-channel strategy, category operations and digitalization. Based on Dada's partnership with JD "Shop Now", a jointly built new business dedicated for JD's on-demand consumer retail section, the two companies can help Nestle accelerate its digital and omni-channel capabilities. Dada Group and Nestle's partnership began in June 2019. In September 2020, they expanded their strategic partnership to create a new data-driven retail model, under which Dada group promoted Nestle's sales growth, brand marketing and user operation. According to JDDJ, Dada's on-demand retail platform, the sales of Nestle on the platform has maintained triple-digit growth in 2019 and 2020 separately.

ShowHide Related Items >><<
NSRGY Nestle
$128.20 /

+0.67 (+0.53%)

DADA Dada Nexus
$21.95 /

+0.32 (+1.48%)

DADA Dada Nexus
$21.95 /

+0.32 (+1.48%)

09/22/21 Morgan Stanley
Dada Nexus upgraded to Overweight from Equal Weight at Morgan Stanley
09/09/21 KeyBanc
Dada Nexus price target lowered to $40 from $47 at KeyBanc
06/09/21
Fly Intel: Top five analyst initiations
06/09/21 Citi
Dada Nexus price target raised to $37 from $36 at Citi
NSRGY Nestle
$128.20 /

+0.67 (+0.53%)

10/22/21 Barclays
Nestle price target raised to CHF 130 from CHF 125 at Barclays
10/21/21 UBS
Nestle price target raised to CHF 135 from CHF 130 at UBS
08/26/21 Societe Generale
Nestle price target raised to CHF 134 from CHF 124 at Societe Generale
07/02/21 Deutsche Bank
Nestle price target raised to CHF 118 from CHF 115 at Deutsche Bank
NSRGY Nestle
$128.20 /

+0.67 (+0.53%)

DADA Dada Nexus
$21.95 /

+0.32 (+1.48%)

  • 03
    Dec
NSRGY Nestle
$128.20 /

+0.67 (+0.53%)

DADA Dada Nexus
$21.95 /

+0.32 (+1.48%)

Recommendations
Nestle price target raised to CHF 130 from CHF 125 at Barclays » 15:43
10/22/21
10/22
15:43
10/22/21
15:43
NSRGY

Nestle

$127.67 /

+1.665 (+1.32%)

Barclays analyst Warren…

Barclays analyst Warren Ackerman raised the firm's price target on Nestle to CHF 130 from CHF 125 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
NSRGY Nestle
$127.67 /

+1.665 (+1.32%)

NSRGY Nestle
$127.67 /

+1.665 (+1.32%)

10/21/21 UBS
Nestle price target raised to CHF 135 from CHF 130 at UBS
08/26/21 Societe Generale
Nestle price target raised to CHF 134 from CHF 124 at Societe Generale
07/02/21 Deutsche Bank
Nestle price target raised to CHF 118 from CHF 115 at Deutsche Bank
07/02/21 Oppenheimer
Seres pact with Nestle brings commercializing path, says Oppenheimer
NSRGY Nestle
$127.67 /

+1.665 (+1.32%)

NSRGY Nestle
$127.67 /

+1.665 (+1.32%)

Recommendations
Nestle price target raised to CHF 135 from CHF 130 at UBS » 15:25
10/21/21
10/21
15:25
10/21/21
15:25
NSRGY

Nestle

$126.00 /

+3.46 (+2.82%)

UBS analyst Guillaume…

UBS analyst Guillaume Delmas raised the firm's price target on Nestle to CHF 135 from CHF 130 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
NSRGY Nestle
$126.00 /

+3.46 (+2.82%)

NSRGY Nestle
$126.00 /

+3.46 (+2.82%)

08/26/21 Societe Generale
Nestle price target raised to CHF 134 from CHF 124 at Societe Generale
07/02/21 Deutsche Bank
Nestle price target raised to CHF 118 from CHF 115 at Deutsche Bank
07/02/21 Oppenheimer
Seres pact with Nestle brings commercializing path, says Oppenheimer
07/01/21 Piper Sandler
Seres Therapeutics price target lowered to $40 from $47 at Piper Sandler
NSRGY Nestle
$126.00 /

+3.46 (+2.82%)

NSRGY Nestle
$126.00 /

+3.46 (+2.82%)

Hot Stocks
Nestle raises FY21 organic sales growth view to 6%-7% from 5%-6% » 06:32
10/20/21
10/20
06:32
10/20/21
06:32
NSRGY

Nestle

$122.54 /

-2.2 (-1.76%)

Nestle said: "We…

Nestle said: "We expect full-year organic sales growth between 6% and 7%. The underlying trading operating profit margin is expected around 17.5%, reflecting initial time delays between input cost inflation and pricing, as well as the one-off integration costs related to the acquisition of The Bountiful Company's core brands. Beyond 2021, our mid-term outlook for continued moderate margin improvement remains unchanged. Underlying earnings per share in constant currency and capital efficiency are expected to increase this year."

ShowHide Related Items >><<
NSRGY Nestle
$122.54 /

-2.2 (-1.76%)

NSRGY Nestle
$122.54 /

-2.2 (-1.76%)

08/26/21 Societe Generale
Nestle price target raised to CHF 134 from CHF 124 at Societe Generale
07/02/21 Deutsche Bank
Nestle price target raised to CHF 118 from CHF 115 at Deutsche Bank
07/02/21 Oppenheimer
Seres pact with Nestle brings commercializing path, says Oppenheimer
07/01/21 Piper Sandler
Seres Therapeutics price target lowered to $40 from $47 at Piper Sandler
NSRGY Nestle
$122.54 /

-2.2 (-1.76%)

NSRGY Nestle
$122.54 /

-2.2 (-1.76%)

Earnings
Nestle reports 9M sales CHF 63.29B vs. CHF 61.91B last year » 06:32
10/20/21
10/20
06:32
10/20/21
06:32
NSRGY

Nestle

$122.54 /

-2.2 (-1.76%)

Organic growth reached…

Organic growth reached 7.6%, with real internal growth of 6.0% and pricing of 1.6%. Growth was supported by continued momentum in retail sales, steady recovery of out-of-home channels, increased pricing and market share gains, Nestle said in a statement. Mark Schneider, Nestle CEO, commented: "We are pleased with Nestle's strong organic growth in the nine months, driven by broad-based contributions from most geographies and categories. The relentless focus of our teams on local execution and agility enabled us to navigate input cost inflation and supply chain constraints. In the third quarter, we increased pricing in a responsible manner, while maintaining strong real internal growth. Investments in innovation, digitalization and sustainability further supported growth by enhancing the relevance and differentiation of our offerings."

ShowHide Related Items >><<
NSRGY Nestle
$122.54 /

-2.2 (-1.76%)

NSRGY Nestle
$122.54 /

-2.2 (-1.76%)

08/26/21 Societe Generale
Nestle price target raised to CHF 134 from CHF 124 at Societe Generale
07/02/21 Deutsche Bank
Nestle price target raised to CHF 118 from CHF 115 at Deutsche Bank
07/02/21 Oppenheimer
Seres pact with Nestle brings commercializing path, says Oppenheimer
07/01/21 Piper Sandler
Seres Therapeutics price target lowered to $40 from $47 at Piper Sandler
NSRGY Nestle
$122.54 /

-2.2 (-1.76%)

NSRGY Nestle
$122.54 /

-2.2 (-1.76%)

Periodicals
Nestle launching plant-based egg, shrimp alternatives, Reuters reports » 11:37
10/06/21
10/06
11:37
10/06/21
11:37
NSRGY

Nestle

$121.05 /

-0.22 (-0.18%)

Nestle is introducing…

Nestle is introducing plant-based alternatives for eggs and shrimp that closely mirror the taste, nutrition and performance of the originals, Reuters' Paul Sandle reports, citing comments made by CEO Mark Schneider. The egg substitute is named Garden Gourmet vEGGie in Europe, containing soy protein and omega-3 fatty acids, while the vegan shrimp is called Vrimp and the move comes as Schneider said the company's vegan products like plant-based burgers and sausages were seeing double-digit growth. Reference Link

ShowHide Related Items >><<
NSRGY Nestle
$121.05 /

-0.22 (-0.18%)

NSRGY Nestle
$121.05 /

-0.22 (-0.18%)

08/26/21 Societe Generale
Nestle price target raised to CHF 134 from CHF 124 at Societe Generale
07/02/21 Deutsche Bank
Nestle price target raised to CHF 118 from CHF 115 at Deutsche Bank
07/02/21 Oppenheimer
Seres pact with Nestle brings commercializing path, says Oppenheimer
07/01/21 Piper Sandler
Seres Therapeutics price target lowered to $40 from $47 at Piper Sandler
NSRGY Nestle
$121.05 /

-0.22 (-0.18%)

NSRGY Nestle
$121.05 /

-0.22 (-0.18%)

Hot Stocks
Financial firms join TNFD to build nature-related risk management framework » 09:18
09/30/21
09/30
09:18
09/30/21
09:18
BAC

Bank of America

$43.09 /

-0.09 (-0.21%)

, AXAHY

AXA

$27.86 /

+0.28 (+1.02%)

, BLK

BlackRock

$856.89 /

-3.49 (-0.41%)

, BNPQY

BNP Paribas

$32.07 /

-0.08 (-0.25%)

, HSBC

HSBC

$26.34 /

+0.38 (+1.46%)

, SSREY

Swiss Re

$21.61 /

+0.2 (+0.93%)

, UBS

UBS

$16.15 /

+0.19 (+1.19%)

, BUD

AB InBev

$57.54 /

-0.855 (-1.46%)

, NGLOY

Anglo American

$17.21 /

+0.13 (+0.76%)

, GSK

GlaxoSmithKline

$38.33 /

+0.28 (+0.74%)

, NSRGY

Nestle

$120.31 /

+1.73 (+1.46%)

Senior executives from…

Senior executives from across financial institutions, corporates and market service providers representing major global markets have been selected to serve for two years as Members of the Taskforce on Nature-related Financial Disclosures. Led by TNFD Co-Chairs Elizabeth Mrema, United Nations Assistant Secretary General and Executive Secretary of the UN Convention on Biological Diversity and David Craig, Former CEO of Refinitiv and Strategic Advisor to London Stock Exchange Group, the Taskforce Members are convening for the first time on the 6th of October to kick off their work developing and delivering a risk management and financial disclosure framework to support a shift in global financial flows away from nature-negative outcomes and towards nature-positive outcomes. The finalised framework is earmarked for release in late 2023. However, a draft beta version will be circulated in early 2022 to be tested and refined via an open-innovation approach with market participants throughout next year. The 30 Taskforce Members have been selected for their sector and geographical coverage and their individual subject-matter expertise across nature and finance that can support TNFD's mission. The Members represent sectors with the largest impact and dependencies on nature, such as agribusiness, the blue economy, food & beverage, mining, construction, infrastructure and others, and are globally representative coming from 14 countries across 5 continents. The Taskforce membership will ultimately consist of up to 35 individuals. Selection of the remaining senior executives is currently underway, bringing in further specialists from sectors and geographies to broaden the Taskforce's geographic and sector coverage and its diversity of expertise. Taskforce members in the TNFD include executives from Bank of America (BAC), Axa (AXAHY), BlackRock (BLK), BNP Paribas (BNPQY), HSBC (HSBC), Swiss Re (SSREY), UBS (UBS), AB InBev (BUD), Anglo American (NGLOY), GSK (GSK), and Nestle (NSRGY). Reference Link

ShowHide Related Items >><<
UBS UBS
$16.15 /

+0.19 (+1.19%)

NSRGY Nestle
$120.31 /

+1.73 (+1.46%)

NGLOY Anglo American
$17.21 /

+0.13 (+0.76%)

HSBC HSBC
$26.34 /

+0.38 (+1.46%)

GSK GlaxoSmithKline
$38.33 /

+0.28 (+0.74%)

BUD AB InBev
$57.54 /

-0.855 (-1.46%)

BLK BlackRock
$856.89 /

-3.49 (-0.41%)

BAC Bank of America
$43.09 /

-0.09 (-0.21%)

AXAHY AXA
$27.86 /

+0.28 (+1.02%)

BAC Bank of America
$43.09 /

-0.09 (-0.21%)

09/29/21 Oppenheimer
Morgan Stanley downgraded to Perform at Oppenheimer on valuation
09/13/21 Odeon Capital
Bank of America upgraded to Buy from Hold at Odeon Capital
09/13/21 Odeon Capital
Bank of America upgraded to Buy from Hold at Odeon Capital
07/19/21 Odeon Capital
Bank of America downgraded to Hold from Buy at Odeon Capital
AXAHY AXA
$27.86 /

+0.28 (+1.02%)

09/10/21 Barclays
AXA price target raised to EUR 26.50 from EUR 26 at Barclays
09/07/21 JPMorgan
AXA price target raised to EUR 28 from EUR 27 at JPMorgan
08/23/21 Deutsche Bank
AXA price target raised to EUR 27.50 from EUR 25 at Deutsche Bank
08/03/21 JPMorgan
AXA price target raised to EUR 27 from EUR 24.95 at JPMorgan
BLK BlackRock
$856.89 /

-3.49 (-0.41%)

08/31/21 Jefferies
BlackRock price target raised to $1,075 from $1,001 at Jefferies
07/15/21 Credit Suisse
BlackRock price target lowered to $1,000 from $1,011 at Credit Suisse
07/15/21 Argus
BlackRock price target raised to $975 from $950 at Argus
07/15/21 Deutsche Bank
BlackRock price target lowered to $1,001 from $1,018 at Deutsche Bank
BNPQY BNP Paribas
$32.07 /

-0.08 (-0.25%)

09/10/21 JPMorgan
BNP Paribas downgraded to Neutral from Overweight at JPMorgan
08/06/21 Berenberg
BNP Paribas price target raised to EUR 52 from EUR 48 at Berenberg
08/03/21 JPMorgan
BNP Paribas price target raised to EUR 65 from EUR 63 at JPMorgan
08/03/21 UBS
BNP Paribas price target raised to EUR 57 from EUR 50 at UBS
HSBC HSBC
$26.34 /

+0.38 (+1.46%)

09/17/21 Barclays
HSBC upgraded to Overweight from Underweight at Barclays
09/17/21 RBC Capital
HSBC upgraded to Outperform from Sector Perform at RBC Capital
08/09/21 RBC Capital
HSBC price target lowered to 450 GBp from 480 GBp at RBC Capital
08/05/21 Morgan Stanley
HSBC price target raised to 450 GBp from 430 GBp at Morgan Stanley
SSREY Swiss Re
$21.61 /

+0.2 (+0.93%)

09/10/21 Barclays
Swiss Re price target lowered to CHF 91 from CHF 93 at Barclays
09/07/21 JPMorgan
Swiss Re price target lowered to CHF 98 from CHF 105 at JPMorgan
09/06/21 JPMorgan
Swiss Re downgraded to Neutral from Overweight at JPMorgan
08/17/21 UBS
Swiss Re price target lowered to CHF 79 from CHF 81 at UBS
UBS UBS
$16.15 /

+0.19 (+1.19%)

09/29/21 RBC Capital
UBS upgraded to Outperform from Sector Perform at RBC Capital
07/26/21 Morgan Stanley
UBS price target raised to CHF 17 from CHF 16 at Morgan Stanley
07/23/21 RBC Capital
UBS price target raised to CHF 17.50 from CHF 17 at RBC Capital
07/21/21 Barclays
UBS price target raised to CHF 14.50 from CHF 13.50 at Barclays
BUD AB InBev
$57.54 /

-0.855 (-1.46%)

09/30/21 Argus
AB InBev downgraded to Hold from Buy at Argus
09/30/21 Argus
AB InBev downgraded to Hold from Buy at Argus
09/16/21
Fly Intel: Top five analyst upgrades
09/16/21 Deutsche Bank
AB InBev upgraded to Buy from Hold at Deutsche Bank
NGLOY Anglo American
$17.21 /

+0.13 (+0.76%)

09/29/21 Morgan Stanley
Anglo American price target lowered to 3,160 GBp at Morgan Stanley
09/28/21 RBC Capital
RBC upgrades Anglo American on 'attractive' valuation after pullback
09/28/21 RBC Capital
Anglo American upgraded to Outperform from Sector Perform at RBC Capital
09/21/21 Berenberg
Anglo American price target lowered to 3,900 GBp from 4,100 GBp at Berenberg
GSK GlaxoSmithKline
$38.33 /

+0.28 (+0.74%)

09/20/21 UBS
GlaxoSmithKline price target lowered to 1,460 GBp from 1,540 GBp at UBS
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
NSRGY Nestle
$120.31 /

+1.73 (+1.46%)

08/26/21 Societe Generale
Nestle price target raised to CHF 134 from CHF 124 at Societe Generale
07/02/21 Deutsche Bank
Nestle price target raised to CHF 118 from CHF 115 at Deutsche Bank
07/02/21 Oppenheimer
Seres pact with Nestle brings commercializing path, says Oppenheimer
07/01/21 Piper Sandler
Seres Therapeutics price target lowered to $40 from $47 at Piper Sandler
UBS UBS
$16.15 /

+0.19 (+1.19%)

NSRGY Nestle
$120.31 /

+1.73 (+1.46%)

HSBC HSBC
$26.34 /

+0.38 (+1.46%)

GSK GlaxoSmithKline
$38.33 /

+0.28 (+0.74%)

BUD AB InBev
$57.54 /

-0.855 (-1.46%)

BLK BlackRock
$856.89 /

-3.49 (-0.41%)

BAC Bank of America
$43.09 /

-0.09 (-0.21%)

UBS UBS
$16.15 /

+0.19 (+1.19%)

NSRGY Nestle
$120.31 /

+1.73 (+1.46%)

NGLOY Anglo American
$17.21 /

+0.13 (+0.76%)

HSBC HSBC
$26.34 /

+0.38 (+1.46%)

GSK GlaxoSmithKline
$38.33 /

+0.28 (+0.74%)

BUD AB InBev
$57.54 /

-0.855 (-1.46%)

BLK BlackRock
$856.89 /

-3.49 (-0.41%)

BAC Bank of America
$43.09 /

-0.09 (-0.21%)

HSBC HSBC
$26.34 /

+0.38 (+1.46%)

GSK GlaxoSmithKline
$38.33 /

+0.28 (+0.74%)

BUD AB InBev
$57.54 /

-0.855 (-1.46%)

BLK BlackRock
$856.89 /

-3.49 (-0.41%)

BAC Bank of America
$43.09 /

-0.09 (-0.21%)

UBS UBS
$16.15 /

+0.19 (+1.19%)

HSBC HSBC
$26.34 /

+0.38 (+1.46%)

GSK GlaxoSmithKline
$38.33 /

+0.28 (+0.74%)

BUD AB InBev
$57.54 /

-0.855 (-1.46%)

BAC Bank of America
$43.09 /

-0.09 (-0.21%)

Periodicals
Nestle expects higher input cost inflation in 2022, Reuters reports » 14:04
09/09/21
09/09
14:04
09/09/21
14:04
NSRGY

Nestle

$124.50 /

-1.18 (-0.94%)

Nestle CFO…

Nestle CFO Francois-Xavier Roger said that the company sees even higher input cost inflation next year than this year, Reuters' Silke Koltrowitz reports. "If we talk of 2022, it is likely that input cost inflation will be higher next year than this year," the executive said at a Barclays consumer staples conference. "Our strategy is to offset anything we receive through pricing. The idea is to pass it on to the trade and to consumers whenever we receive it," he added, noting there would be a delay. Reference Link

ShowHide Related Items >><<
NSRGY Nestle
$124.50 /

-1.18 (-0.94%)

NSRGY Nestle
$124.50 /

-1.18 (-0.94%)

08/26/21 Societe Generale
Nestle price target raised to CHF 134 from CHF 124 at Societe Generale
07/02/21 Deutsche Bank
Nestle price target raised to CHF 118 from CHF 115 at Deutsche Bank
07/02/21 Oppenheimer
Seres pact with Nestle brings commercializing path, says Oppenheimer
07/01/21 Piper Sandler
Seres Therapeutics price target lowered to $40 from $47 at Piper Sandler
NSRGY Nestle
$124.50 /

-1.18 (-0.94%)

NSRGY Nestle
$124.50 /

-1.18 (-0.94%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.